NEW YORK – Mission Bio today announced a comarketing agreement for its Tapestri single-cell analysis platform with Agilent Technologies.
The deal will help bring Tapestri to cancer researchers in North America, Mission Bio said in a statement. The firms did not specify which Agilent products Tapestri will marketed together.
Financial and other details of the agreement were not disclosed. Agilent has been investing in South San Francisco-based Mission Bio since 2014 and co-led the firm's 2018 $30 million Series B financing round.
"This targeted sequencing method at the single-cell level complements our class-leading genomics products, providing a more comprehensive oncology offering for our customers," Agilent VP Kevin Corcoran said in a statement.
"Leveraging Agilent's vast US commercial footprint gives us significant reach to additional customers, providing them with the tools to develop treatments and potentially cures for cancer," Mission Bio CCO Darrin Crisitello added.
Tapestri offers the ability to analyze DNA and protein changes in single cells. The Agilent deal follows a 2019 distribution agreement between Mission Bio and Novogene to bring Tapestri to the Chinese market.
The firms noted that Agilent has been using Tapestri in quality control for its internal CRISPR genome editing research, to analyze off-target effects in therapeutic development.